MARKET

ENTA

ENTA

Enanta Pharmaceuticals Inc
NASDAQ
12.83
-0.33
-2.51%
After Hours: 12.83 0 0.00% 16:15 08/17 EDT
OPEN
13.13
PREV CLOSE
13.16
HIGH
13.32
LOW
12.59
VOLUME
314.79K
TURNOVER
--
52 WEEK HIGH
17.15
52 WEEK LOW
7.05
MARKET CAP
373.68M
P/E (TTM)
-5.3210
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ENTA last week (0810-0814)?
Weekly Report · 19h ago
Enanta Pharmaceuticals Flags Ongoing Uncertainty as 2025 Risk Factors Continue to Shape 2026 Outlook
TipRanks · 4d ago
Enanta Pharmaceuticals (ENTA) Stock Faces Revenue Slip And Wider Losses
Simply Wall St · 6d ago
H.C. Wainwright Sticks to Their Buy Rating for Enanta Pharmaceuticals (ENTA)
TipRanks · 6d ago
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates
NASDAQ · 08/10 21:10
*Enanta Pharmaceuticals: Cash Runway Expected to Fund Ops Into Fiscal 2029 >ENTA
Dow Jones · 08/10 20:12
*Enanta Pharma On Track to File IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor and to Select MRGPRX2 Development Candidate, in 2H >ENTA
Dow Jones · 08/10 20:11
Enanta Pharma GAAP EPS of -$0.67 misses by $0.16, revenue of $14.35M misses by $2.47M
Seeking Alpha · 08/10 20:07
More
About ENTA
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. The Company’s clinical programs are focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including receptor tyrosine kinase (KIT) and STAT6 inhibition. The Company has two clinical-stage product candidates for RSV, which are zelicapavir and EDP-323. Glecaprevir, a protease inhibitor discovered by the Company, is part of one of the treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in various countries under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). The Company also has development programs in virology for SARS-CoV-2 and Hepatitis B virus.

Webull offers Enanta Pharmaceuticals Inc stock information, including NASDAQ: ENTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENTA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ENTA stock methods without spending real money on the virtual paper trading platform.